- Tytuł:
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet Oncology September 2022 23(9):1133-1144
Czasopismo naukowe